Trials / Completed
CompletedNCT00265993
Enoxaparin in Acute Venous Thromboembolic Disease
The Efficacy of Subcutaneous Enoxaparin Once Daily in the Treatment of Acute Venous Thromboembolic Disease: an Open-labelled, Non-comparative, Multicentric, Phase IV Trial
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 251 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Study objectives : * To evaluate the efficacy/safety profile of enoxaparin once a day treatment in acute venous thromboembolic disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | enoxaparin | * All patients will be treated with enoxaparin 1.5 mg/kg, once a day, subcutaneously for up to 10 days. * Long-term oral anticoagulation will be started in all patients after 24 hours of initiation of enoxaparin treatment and continued at least for 3 months. |
Timeline
- Start date
- 2004-12-01
- Primary completion
- 2009-01-01
- Completion
- 2009-01-01
- First posted
- 2005-12-15
- Last updated
- 2010-02-03
Locations
1 site across 1 country: Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT00265993. Inclusion in this directory is not an endorsement.